A- A A+

Adverse drug reactions with naltrexone: Experience from an addiction treatment center. 

Sarkar S, Addagadda SS, Bhatia G, Chadda RK. 

Indian J Psychiatry. 2021 Mar-Apr;63(2):206-207. doi: 10.4103/psychiatry.IndianJPsychiatry_94_20. Epub 2021 Apr 14. PMID: 34194072; PMCID: PMC8214125.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214125/

Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. 

Kosten T, Aharonovich E, Nangia N, Zavod A, Akerman SC, Lopez-Bresnahan M, Sullivan MA. 

Addict Behav. 2020 Dec;111:106538. doi: 10.1016/j.addbeh.2020.106538. Epub 2020 Jul 3. PMID: 32777606.

https://www.sciencedirect.com/science/article/pii/S0306460320306687

Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder. 

Perez-Macia V, Martinez-Cortes M, Mesones J, Segura-Trepichio M, Garcia-Fernandez L. 

Patient Prefer Adherence. 2021 May 18;15:999-1015. doi: 10.2147/PPA.S277861. PMID: 34040354; PMCID: PMC8140930.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140930/

Life threatening opioid withdrawal syndrome due to inadvertent naltrexone administration and lifesaving result by clonidine. 

Kurmi J, Choudhury HA. 

Indian J Psychiatry. 2020 Nov-Dec;62(6):742-743. doi: 10.4103/psychiatry.IndianJPsychiatry_649_19. Epub 2020 Dec 12. PMID: 33896990; PMCID: PMC8052871.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052871/

Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial

Collins, Susan E et al.

The Lancet Psychiatry, Volume 8, Issue 4, 287 - 300 

https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30489-2/fulltext

Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study). 

Weimand BM, Solli KK, Reichelt WH, Tanum L. 

Contemp Clin Trials Commun. 2021 Feb 10;21:100728. doi: 10.1016/j.conctc.2021.100728. PMID: 33665469; PMCID: PMC7900681.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900681/

A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. 

Sibai M, Mishlen K, Nunes EV, Levin FR, Mariani JJ, Bisaga A. 

Am J Drug Alcohol Abuse. 2020 May 3;46(3):289-296. doi: 10.1080/00952990.2019.1700265. Epub 2019 Dec 20. PMID: 31860366; PMCID: PMC7260104.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260104/

Adapting treatment length to opioid‐dependent individuals’ needs and preferences: a 2‐year follow‐up to a 1‐year study of extended‐release naltrexone. 

Solli, K. K., Opheim, A., Latif, Z., Krajci, P., Benth, Jė. Š., Kunoe, N., and Tanum, L. (2021) 

Addiction, doi.org/10.1111/add.15378.

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15378

Naltrexone-Associated Non-ST-Elevated Myocardial Infarction. 

Gubitosa JC, Terwillliger T, Ukazu A, Gordon E. 

Cureus. 2020 Oct 27;12(10):e11198. doi: 10.7759/cureus.11198. PMID: 33269129; PMCID: PMC7703987.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703987/

Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management. 

Sadee W, Oberdick J, Wang Z. 

Molecules. 2020 Sep 11;25(18):E4163. doi: 10.3390/molecules25184163. PMID: 32932935.

https://www.mdpi.com/1420-3049/25/18/4163

Naloxone-Induced Acute Opioid Withdrawal in a Stabilized Extended-Release Naltrexone-Treated Patient. 

Spitzberg AJ, Urner EM, Wirshing WC. 

Prim Care Companion CNS Disord. 2020 Sep 17;22(5):20l02590. doi: 10.4088/PCC.20l02590. PMID: 32942347.

https://www.psychiatrist.com/pcc/article/pages/opioid-withdrawal-syndrome-following-naloxone-challenge.aspx

Improving naltrexone compliance and outcomes with putative pro-dopamine regulator KB220, compared to treatment as usual. 

Blum K, Lott L, Baron D, Smith DE, Badgaiyan RD, Gold MS. 

J Syst Integr Neurosci. 2020 May 30;7:10.15761/JSIN.1000229. doi: 10.15761/JSIN.1000229. PMID: 32934823; PMCID: PMC7489288.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489288/

Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. 

Krieter P, Gyaw S, Chiang CN, Crystal R, Skolnick P.  

J Clin Pharmacol. 2019;59(7):947-957. doi:10.1002/jcph.1384

https://pubmed.ncbi.nlm.nih.gov/30698833/

Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. 

Kosten T, Aharonovich E, Nangia N, et al. 

Addict Behav. 2020;111:106538. doi:10.1016/j.addbeh.2020.106538

https://www.sciencedirect.com/science/article/pii/S0306460320306687

Letter To The Editor - Drug Eruption After Sustained Release Naltrexone Pellet Implantation -- Editöre Mektup - Yavaş Salınımlı Naltrekson İmplant Uygulaması Sonrası Gelişen İlaç Erüpsiyonu.

Ak S, Can Gürel Ş. 

Turk Psikiyatri Derg. 2020;31(2):146-147. 

http://www.turkpsikiyatri.com/en/pdfRedirecter.aspx?id=1208

Potential uses of naltrexone in emergency department patients with opioid use disorder. 

Bradley ES, Liss D, Carreiro SP, Brush DE, Babu K. 

Clin Toxicol (Phila). 2019;57(9):753-759. doi:10.1080/15563650.2019.1583342

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908461/

USA. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document.

This updated Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. (SAMHSA - Substance Abuse & Mental Health Services Administration, USA, Mai 2020)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-02-01-006.pdf

Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM.

JAMA Netw Open. 2020 Feb 5;3(2):e1920622. doi: 10.1001/jamanetworkopen.2019.20622.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760032

Naltrexone use in pregnancy: a time for change.

Caritis SN, Venkataramanan R.

Am J Obstet Gynecol. 2020 Jan;222(1):1-2. doi: 10.1016/j.ajog.2019.08.041. 

https://doi.org/10.1016/j.ajog.2019.08.041

A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.

Sullivan MA, Bisaga A, Pavlicova M, Carpenter KM, Choi CJ, Mishlen K, Levin FR, Mariani JJ, Nunes EV.

Am J Psychiatry. 2019 Feb 1;176(2):129-137. doi: 10.1176/appi.ajp.2018.17070732. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358483/

Acceptability and efficacy of naltrexone for criminal justice‐involved individuals with opioid use disorder: a systematic review and meta‐analysis.

Bahji, A., Carlone, D., and Altomare, J. ( 2019) 

Addiction, doi.org/10.1111/add.14946.

Abstract

https://onlinelibrary.wiley.com/doi/abs/10.1111/add.14946?campaign=wolacceptedarticle

Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.

Friedmann PD, Wilson D, Hoskinson R Jr, Poshkus M, Clarke JG.

J Subst Abuse Treat. 2018 Feb;85:45-48. doi: 10.1016/j.jsat.2017.04.010. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648627/

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.

Velasquez M, Flannery M, Badolato R, Vittitow A, McDonald RD, Tofighi B, Garment AR, Giftos J, Lee JD.

Addict Sci Clin Pract. 2019 Oct 1;14(1):37. doi: 10.1186/s13722-019-0166

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771097/

Rizmoic / Nalmedine 200 Mikrogramm Filmtabletten - ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS

Rizmoic wird angewendet zur Behandlung von Opioid-induzierter Obstipation (OIC, opioid-induced constipation) bei Erwachsenen, die früher bereits mit einem Abführmittel behandelt wurden. (Europäische Arzneimittel-Agentur, 2019)

https://www.ema.europa.eu/en/documents/product-information/rizmoic-epar-product-information_de.pdf

A Review of Samidorphan: A Novel Opioid Antagonist.

Chaudhary AMD, Khan MF, Dhillon SS, Naveed S.

Cureus. 2019 Jul 15;11(7):e5139. doi: 10.7759/cureus.5139. Review.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741386/

Letter to the Editor: Response to Darke S, et al. Circumstances of death of opioid users being treated with naltrexone. 

Streel, E., and Brewer, C. ( 2019)

Addiction, First published: 16 September 2019, doi.org/10.1111/add.14826

https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.14826

Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.

Nunes EV, Bisaga A, Krupitsky E, Nangia N, Silverman BL, Akerman SC, Sullivan MA.

Addiction. 2019 Jul 17. doi: 10.1111/add.14735.

Abstract 

https://www.ncbi.nlm.nih.gov/pubmed/31313402

Circumstances of death of opioid users being treated with naltrexone.

Darke S, Farrell M, Duflou J, Larance B, Lappin J.

Addiction. 2019 Jul 6. doi: 10.1111/add.14729. 

Abstract

https://onlinelibrary.wiley.com/doi/abs/10.1111/add.14729

Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.

Wachman EM, Saia K, Miller M, Valle E, Shrestha H, Carter G, Werler M, Jones H.

Clin Ther. 2019 Jul 27. pii: S0149-2918(19)30346-7. doi: 10.1016/j.clinthera.2019.07.003.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31358302

Opiate Antagonists Do Not Interfere With the Clinical Benefits of Stimulants in ADHD: A Double-Blind, Placebo-Controlled Trial of the Mixed Opioid Receptor Antagonist Naltrexone.

Spencer TJ, Bhide P, Zhu J, Faraone SV, Fitzgerald M, Yule AM, Uchida M, Spencer AE, Hall AM, Koster AJ, Biederman J.

J Clin Psychiatry. 2018 Jan/Feb;79(1). pii: 16m11012. doi: 10.4088/JCP.16m11012.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438372/